BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Seifert LL, Schindler P, Schoster M, Weller JF, Wilms C, Schmidt HH, Maschmeier M, Masthoff M, Köhler M, Heinzow H, Wildgruber M. Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin. J Clin Med 2021;10:4763. [PMID: 34682886 DOI: 10.3390/jcm10204763] [Reference Citation Analysis]
2 Sohal A, Green V, Sandhu S, Roytman M. Identifying areas of improvement in nursing knowledge regarding hepatic encephalopathy management. J Community Hosp Intern Med Perspect 2021;11:722-6. [PMID: 34567473 DOI: 10.1080/20009666.2021.1954784] [Reference Citation Analysis]
3 Rega D, Aiko M, Peñaranda N, Urios A, Gallego JJ, Giménez-Garzó C, Casanova F, Fiorillo A, Cabrera-Pastor A, San-Miguel T, Ipiens C, Escudero-García D, Tosca J, Montón C, Ballester MP, Ballester J, Aparicio L, Ríos MP, Durbán L, Mir A, Kosenko E, Cases P, Felipo V, Montoliu C. Patients with Minimal Hepatic Encephalopathy Show Altered Thermal Sensitivity and Autonomic Function. J Clin Med 2021;10:E239. [PMID: 33440769 DOI: 10.3390/jcm10020239] [Reference Citation Analysis]
4 Koepf US, Scheidt S, Hischebeth GTR, Strassburg CP, Wirtz DC, Randau TM, Lutz P. Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis. BMC Infect Dis 2022;22:389. [PMID: 35439971 DOI: 10.1186/s12879-022-07379-2] [Reference Citation Analysis]
5 Manzhalii E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment. World J Hepatol 2022; 14(3): 634-646 [DOI: 10.4254/wjh.v14.i3.634] [Reference Citation Analysis]
6 Scarpellini E, Luigiano C, Svegliati-Baroni G, Dumitrascu D, Larussa T, Santori V, Luzza F, Abenavoli L. Liver Cirrhosis Complications Management at the Emergency Department. Rev Recent Clin Trials 2020;15:331-8. [PMID: 32493202 DOI: 10.2174/1574887115666200603160816] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
8 Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis. Dig Liver Dis 2021;53:817-23. [PMID: 34011479 DOI: 10.1016/j.dld.2021.04.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
10 Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Reference Citation Analysis]
11 Wernberg CW, Schaffalitzky de Muckadell OB, Vilstrup H, M Lauridsen M. Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis. PLoS One 2019;14:e0226283. [PMID: 31830113 DOI: 10.1371/journal.pone.0226283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Rajpurohit S, Musunuri B, Shailesh, Mohan PB, Shetty S. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.01.012] [Reference Citation Analysis]
13 Gupta H, Min B, Ganesan R, Gebru YA, Sharma SP, Park E, Won S, Jeong J, Lee S, Cha M, Kwon G, Jeong M, Hyun J, Eom J, Park H, Yoon S, Choi M, Kim D, Suk K. Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. Biomedicines 2022;10:550. [DOI: 10.3390/biomedicines10030550] [Reference Citation Analysis]
14 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021;74:1660-73. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
15 Woodland H, Hudson B, Forbes K, McCune A, Wright M; British Association for the Study of the Liver (BASL) End of Life Special Interest Group. Palliative care in liver disease: what does good look like? Frontline Gastroenterol 2020;11:218-27. [PMID: 32419913 DOI: 10.1136/flgastro-2019-101180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Han W, Zhang H, Han Y, Duan Z. Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy. Metab Brain Dis. 2020;35:869-881. [PMID: 32495311 DOI: 10.1007/s11011-020-00539-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]